Menu Search
Equities

Argent Biopharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
H5O0:STU

Argent Biopharma Ltd

Actions
  • Price (EUR)0.025
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-74.23%
  • Beta0.2210
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Argent BioPharma Limited is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The Company’s assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The Company’s proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. It focuses on urgent unmet needs in the central nervous system (CNS) and systemic inflammation. Its product pipeline includes CimetrA, CannEpil, CogniCann and others. CannEpil is a refractory epilepsy seizure control treatment. CogniCann is an investigational oral spray developed by the Company to help manage symptoms associated with dementia and Alzheimer’s disease. The Company has a patient base in Australia, the United Kingdom, Brazil, and Ireland.

  • Revenue in AUD (TTM)180.56k
  • Net income in AUD-17.84m
  • Incorporated2005
  • Employees--
  • Location
    Argent Biopharma LtdSuite 1, 295 Rokeby RoadSUBIACO 6008AustraliaAUS
  • Phone+61 86555-2950
  • Fax+61 89389-2099
  • Websitehttps://argentbiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.